Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 and MZE782. The financing round included the conversion of ...

Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, ... Janus Henderson Investors and Logos Capital also participated.

Guggenheim analyst Debjit Chattopadhyay initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $19 price target The company has advanced three small molecules into clinical ...

Summary. Maze Therapeutics aims to raise $100 million in an IPO to fund clinical trials for its kidney and related disease treatments. The company’s lead candidate, MZE829, is in Phase 2 trials ...

Fintel reports that on July 8, 2025, Wedbush initiated coverage of Maze Therapeutics (NasdaqGM:MAZE) with a Outperform recommendation. Analyst Price Forecast Suggests 58.85% Upside As of June 21, 2025 ...

Maze said it earned $9.03 million for the nine months ended Sept. 30, 2024, compared with a loss of $73.84 million in the year-ago period. The terms of the IPO were not disclosed in the offering.

Leerink initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and $28 price target Maze is a clinical-stage biotechnology company focused on leveraging human genetics to develop ...

SOUTH SAN FRANCISCO, Calif., December 03, 2024--Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision ...

Financing Co-Led by Frazier Life Sciences and Deep Track Capital, with Janus Henderson Investors and Logos Capital Participating Maze Therapeutics, a clinical-stage biopharmaceutical company ...